Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
Other Routine +

Bausch + Lomb Announces Second R&D "Teach-in" Webinar

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

By The Northwire Desk — AI Analysis May 06, 2026 · 07:15 BLCO · 21.85 BAUSCH + LOMB CORPORATION
Executive Summary
  • Bausch + Lomb announced a second R&D "Teach-in" webinar scheduled for June 1, 2026.
  • The event will feature CEO Brent Saunders, CFO Sam Eldessouky, and CMO Yehia Hashad.
  • Focus areas include two specific contact lens technologies: a bioactive contact lens (first new material in 25 years) and a silicone hydrogel daily lens for myopia progression.
  • This follows the April 30 announcement of over 40 scientific studies at ARVO, which also highlighted pipeline assets like BL1107 and BL1312.
  • The webinar is hosted by Citi as part of their "Head, Shoulders, Knees, and Toes" series.
Material Impact
  • The announcement is a follow-up to the Q1 2026 earnings release (April 29) which already raised full-year guidance significantly.
  • Pipeline assets discussed (Bioactive lens, Myopia lens) were previously disclosed in the November 2025 Investor Day presentation with launch timelines of 2028-2029.
  • No new financial data, regulatory approvals, or M&A activity is introduced that would alter the valuation model established in Q1 earnings.
  • The market likely anticipated this communication given the ARVO announcement just days prior and the scheduled Investor Day follow-ups.
  • Impact is incremental to the positive sentiment generated by the Q1 guidance raise; does not constitute a material shift in risk/reward profile.
BLCO · Price
Company Overview
  • Company: Bausch + Lomb Corp., a global eye health company operating in Vision Care, Surgical, and Pharmaceuticals segments.
  • Flagship Projects:
    • Pharmaceuticals: MIEBO (dry eye) and XIIDRA (lifitegrast), driving significant revenue growth (+33% and +30% respectively).
    • Vision Care: LUMIFY (redness reliever) and Biotrue contact lenses; new bioactive lens pipeline in development.
    • Surgical: enVista IOLs, Stellaris Elite systems, and Elios glaucoma laser system.
  • Strategic Focus: Transformation initiative "Vision '27" targeting margin expansion and deleveraging.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 21, 2026 · 07:15

Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Other May 20, 2026 · 16:49

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results

Regulatory May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other